28.6 C
Vientiane
Sunday, October 5, 2025
spot_img
Home Blog Page 3043

Lockton Asia Appoints Ben Son as Korea CEO

SEOUL, SOUTH KOREA – Media OutReach – 1 November 2022 – Lockton, the world’s largest privately held brokerage firm providing insurance, risk management, people solutions and retirement consulting services, has announced the appointment of Ben Son as Chief Executive Officer of Lockton Companies (Korea) Inc.

Ben Son will be succeeding current CEO Juyeol Lee as the company’s new Chief Executive Officer. Juyeol Lee will remain President of Lockton Korea, working in conjunction with Ben and driving one of the key areas of the Korean business and various initiatives. Juyeol has been with Lockton Korea since 2001.

“We are excited to welcome Ben and his team to Lockton Korea, adding expertise and marketing capabilities in reinsurance and retail will unlock further opportunities for the company to deepen partnerships with the country’s leading financial institutions. Combining the teams’ expertise, reputation, relationships, and revenue, will result in continued acceleration of Lockton Korea’s growth trajectory and position as a leading insurance brokerage,” said Juyeol Lee, President of Lockton Korea.

Ben has 32 years of broad and successful experience in P&C, reinsurance and retail across the insurance brokerage industry. He established his own brokerage company, ESOP, in 2019 initially with a team of 8 specialising in reinsurance and retail, with clients from financial institutions, investment banks, asset management companies, private equity firms and more. The company recorded revenue of US$2.2 million in 2021.

Prior to setting up his own brokerage, Ben started his career in 1990 as an underwriter and adjuster in Marine insurance and gained extensive experience in P&C. He also held senior positions with HIS Korea, AON and Miller Korea. His key specialties include reinsurance for P&C, Engineering, Cargo, Hull, P&L and Treaty.

“As we welcome Ben, Lockton Korea will embark on another phase of the company’s journey,” said Warren Merritt, CEO of Lockton Asia, “Ben will be leading our Korean business with continued focus on reinsurance and retail operations. With him at the helm and strengthening the senior management team, we are confident in achieving great things by building on our operational excellence, reinforcing our collaborative culture, as well as raising our brand profile and industry standing.”

Ben’s business operating philosophy calls for transparent management with clear development opportunities for all employees. He believes hard work should be rewarded fairly. Ben holds a bachelor’s degree in public administration from Korea University.

“I am honoured and truly proud to be appointed to lead the team at Lockton Korea. Its expertise, market position and especially its people, making it one of Korea’s most dynamic insurance brokerages, offering what I believe is an unrivalled customer proposition in a rapidly evolving industry. I look forward to working with the team and in partnership with all stakeholders, to lead the business in this exciting market.” said Ben Son, CEO of Lockton Korea.

Hashtag: #LocktonAsia

About Lockton Korea

Lockton Korea is a key member of the Asia operations of Lockton, a world-leading privately held insurance brokerage with 9,500+ associates doing business in over 125 countries, focusing primarily on clients’ risk, insurance and people needs. With expertise that spans the globe, Lockton delivers the deep understanding needed to accomplish remarkable results. At Lockton, we are passionate about serving our clients, developing our associates, and giving back to our communities. For more information, please visit .

The Eyes Inc. Provides Troubleshooting Services for Visual Discomfort With Progressive Lenses

SINGAPORE – Media OutReach – 1 November 2022 – The Eyes Inc., an optical store in Singapore, provides progressive lenses troubleshooting services, which are available at their Ang Mo Kio store.

2 in 10 people who wear progressive lenses experience adverse symptoms, such as double vision, side blurry aberration, wavy vision, headaches, and blurred vision. While vision problems induced by wearing progressive lenses are common, they can be resolved with the help of advanced technologies and proper fitting technique. The Eyes Inc. is able to aid in this, having been founded and helmed by a qualified optometrist with over 15 years of experience and expertise in progressive lenses troubleshooting.

The Eyes Inc. provides an obligation-free general eye check before proceeding with the troubleshooting process. Some basic questions will be asked to better understand individual lifestyle, issues, work habits, and needs. With this information, they can provide a more tailored recommendation for one’s eyes with better insight into their pain points. The optometrist will then move on to data extraction, in which the existing pair of eyeglasses will be used to discern the root of an individual’s vision issues. Next, an extensive eye check will be carried out during which refraction, ocular motility, and existence of cataracts are assessed. Finally, a briefing will be provided on everything related to the prescription, eye condition, and the cause of any vision discomfort.

Since its establishment, The Eyes Inc. has been a one-stop shop for eye-related issues such as double vision, eye strain, progressive lens discomfort, dyslexia, and more. The optical shop also understands how crucial comfortable and clear vision is to everyone, and ensures that glasses are customised specifically to each individual’s needs or eye condition. With their progressive lens troubleshooting service available, The Eyes Inc. hopes to continue assisting individuals facing problems with their progressive lenses.

For assistance/ enquiries on your pair of progressive lenses, visit https://www.theeyesinc.sg/progressive

Hashtag: #TheEyesInc

The issuer is solely responsible for the content of this announcement.

Vertica and KMS Solutions tap into the $90B Data and Analytics Market in APAC

SINGAPORE – Media OutReach – 1 November 2022 – From the report of GlobalData, the APAC Data and Analytics market is set to reach US89.6 billion in 2022, showing the potential of this industry. The rising demands for analytical database software in the APAC market have generated the potential playground for both local and global data analytics corporations.

By participating in this playground, Vertica – a leading analytics data warehouse that can help enterprises handle an enormous amount of information in real-time, derive greater predictive analytics and improve data quality with Unified Analytics Platform. This solution combines the power of a high-performance MPP query engine with advanced analytics and machine learning to provide corporations with actionable analytical insights quickly and fit for purpose. In addition, Vertica has brought data analytics solutions to 1000+ corporations across all industries, such as Financial Services, Healthcare, Manufacturing, etc.

To adapt to differences in culture, laws, and regulations, as well as customize data analytics solutions that suit the specific requirements of local businesses, Vertica trusted KMS Solutions – a regional software consulting firm with 13 years of experience in this industry with solid footprint in Vietnam.

KMS Solutions has long been recognized as a trusted partner in providing tailored analytical solutions to global organizations. The company has offered various data analytics services, including Data as-a-service, Data warehouse, Customer data platform, and Data Migration, to help clients make insightful operational decisions. KMS clearly understands the obstacles and opportunities of the APAC market, as well as the specific requirements of local enterprises for data analytics services

“It’ll be challenging for a company to deal with data proliferation itself. With a common goal of assisting businesses in collecting data quickly, exploring data interactively, and making data-driven decisions, we’re committed to providing actionable insights at scale through the high-performance process of machine learning and advanced analytics,“ said Damien Velly, ES&A Director of KMS Solutions.

This solution help remove scale, performance, and capacity constraints and lets corporations leverage multiple deployment options to suit their specific needs. From that, corporations can take advantage of useful insights to improve customer experience and increase business performance.

Hashtag: #Vertica #KMSSolutions

Lightnet Group Partners with Raffles Family Office to Expand Payment Ecosystem to Revo – Asia’s First Digital Asset-Based Multi-Family Office Platform

SINGAPORE – Media OutReach – 1 November 2022 – Singapore-based Lightnet Group (“Lightnet”) announced today the completion of Raffles Family Office’s (“Raffles FO”) strategic investment. The funding will support Lightnet’s ongoing operations and help enhance the development of Lightnet products and solutions.

As part of the transaction, Lightnet will secure a strategic stake in Raffles FO’s digital asset wealth management platform, Revo. The partnership will provide valuable technical support and payment infrastructure to drive and deliver success for both parties, by enabling Lightnet to expand its payment ecosystem to cover institutional funds transfer, a major component of Raffles FO’s service offering to support ultra-high-net-worth (UHNW) families in the region through Revo. The partnership reaffirms Lightnet’s vision to revolutionise the payments and remittance space with next generation infrastructure and services across the entire spectrum, from the unbanked or underbanked, to wealthy individuals and family offices.

Raffles Family Office Group CEO Chi-man Kwan said:

“We are delighted to participate in the strategic investment in Lightnet which focuses on the next generation financial infrastructure. At Raffles Family Office, we are committed to driving the development of a wealth management platform built for the digital future and synergies with like-minded innovators in a collaborative ecosystem to enable and optimize digitalization in finance. We will continue to play our part in revolutionizing the world of finance, working together with partners to unlock the potential of blockchain technology.”

Lightnet Co-Founder and Chairman, Chatchaval Jiaravanon, said:

This agreement will see more adoption of Lightnet’s next generation financial infrastructure. This is key to expanding our payments and remittance services. We are very excited to be able to join forces with Raffles Family Office and hope this agreement will bring meaningful growth for our payments infrastructure and the asset-based platform. Lightnet’s network will provide borderless and formless financial mobility infrastructure for Revo digital asset wealth management platform to move the fund anywhere in the world.

Hashtag: #LightnetGroup

The issuer is solely responsible for the content of this announcement.

About Lightnet Group

Lightnet Group is a Singapore-headquartered fintech group with the mission of promoting financial mobility and inclusivity. Lightnet Group empowers unbanked populations and SME trade finance with an inclusive international remittance ecosystem. The Lightnet Group’s international remittance ecosystem adopts, in parallel to existing and traditional documentation and process, the Velo Protocol as its blockchain transaction documentation protocol and positions itself as the premiere clearing and settlement network for the Asia Pacific region by connecting existing financial systems with its network of cash agents and wallets. Lightnet is backed by CP Group Family members as well as major investors in the region including UOB Venture Management, Hanwha Investments & Securities, 7Bank, Unipresident, Hashkey, and many others. To learn more, please visit https://.

About Raffles Family Office

Raffles Family Office (Raffles FO) is an award-winning multi-family office that offers a full suite of wealth management services for ultra-high net worth individuals. With an integrated platform that combines independence with advisory expertise across a broad range of asset classes and an expansive global partnership network built for seamless collaboration with the world’s leading financial institutions, the firm is uniquely placed to provide comprehensive, lasting and highly bespoke wealth growth and preservation solutions. Raffles FO is headquartered in Hong Kong and has branch offices in multiple Asian financial centres, including Singapore, Shanghai, Beijing and Taipei. For additional information, visit

About Revo Digital Family Office

Revo is Asia’s first digital-assets-focused multi-family office and the platform of choice for ultra-high net worth individuals looking to join the most important investment revolution of our time. Purpose-built to perpetually evolve in line with the ongoing digitisation of assets and wealth management solutions, Revo’s current offerings include digital asset and wallet aggregation, independent digital asset management, private wealth advice, and gatekeeper services that allow for succession planning with innovation in mind. Revo was co-founded by leading Asian multi-family office Raffles Family Office and internationally acclaimed digital asset technology firm Huobi Technology Holdings. For additional information, visit .

Volt Resources discusses joint development agreement with 24M Technologies

SYDNEY, AUSTRALIA – News Direct – 1 November – Volt Resources Ltd (ASX: VRC) managing director Trevor Matthews speaks with Andrew Scott from Proactive about two recent announcements – a joint development agreement with 24M Technologies and a graphite supply MoU. Matthews discusses test-work using graphite from its Ukraine operations. “We are looking forward to continuing our battery anode material qualification work with 24M and its licensees,” says Matthews.

PressReleaseTMPIlIJY6.jpg

Hashtag: #VoltResources

The issuer is solely responsible for the content of this announcement.

Cushman & Wakefield Highly Commended in Valuation Team and Agency Team of the Year at RICS Hong Kong Awards 2022

  • Highly commended for Valuation Team of the Year award
  • Highly commended for Agency Team of the Year: Retail Team award

HONG KONG SAR – Media OutReach – 31 October 2022 – Cushman & Wakefield, a leading global real estate services firm, has again been recognized for its leading service excellence and industry achievements at the Royal Institution of Chartered Surveyors (RICS) Awards in Hong Kong. The firm was cited as Highly Commended in the 2022 valuation team and agency team of the year.

combine-1.png
Highly Commended – Valuation Team of the Year: Hong Kong Valuation & Advisory Services team
Highly Commended – Agency Team of the Year: Hong Kong Retail Team in partnership with Gaw Capital

Highly Commended — Valuation Team of the Year

Cushman & Wakefield’s Valuation and Advisory Services team again won credit for upholding the highest international standards and imbuing confidence to end-users for objectivity, independence and reliability. “From Zero to Hero”, we are the Visionary Pioneer among industry peers in fusing Sustainability & ESG considerations to our regular valuation workstreams.

Andrew Chan, Managing Director & Head of Valuation & Advisory Services, Greater China, Cushman & Wakefield, said, “We are thrilled to receive such high recognition in the valuation services category award in Hong Kong this year. This commendation is the result of a year of notable achievement for the team here, marked by the full operational deployment of our pioneering Real Estate Sustainability Services Platform (RESSP). I am proud to say that RESSP is a true industry first, bringing sustainability and ESG considerations into the regular valuation workstream in a form that sets us apart from traditional professional consultancies. I congratulate the team on their commitment, passion and success, and together we envision a fully-upgraded valuation practice that will be a game-changer for the industry and contributes to a sustainable built environment towards the future.”

Highly Commended — Agency Team of the Year: Retail Team in Partnership with Gaw Capital

The firm’s Retail Services team continued the success generated at the RICS Hong Kong awards for the fifth consecutive years, with a Highly Commended award for trendsetting work in creating the all-new “Wellness Real Estate” concept, with the vision fully materialized at the H.A.N.D.S. shopping mall project in Tuen Mun, in close partnership with Gaw Capital Asset Management.

Kevin Lam, Executive Director & Head of Retail Services, Hong Kong, Cushman & Wakefield, commented, “We are extremely proud to be recognized again as an industry leader, demonstrating our innovation and vision to bring a fresh new retail concept to life here in Hong Kong. It is always hard to kickstart a new trend, but in Wellness Real Estate we truly believe we are building a sustainable retail lifestyle, one that can transcend time and property types, and which is intended to endure as a post-pandemic new norm. The H.A.N.D.S. mall project has been highly successful, and again demonstrates our positioning and track record as a trusted partner and innovator to both landlords and tenants alike into the future.”

K K Chiu, Chief Executive, Greater China, Cushman & Wakefield, said: “Congratulations to our professional teams on their stellar performances. These Highly Commended awards at the RICS Awards in Hong Kong again demonstrate the results of our joint commitment to client-centric service and innovation in the industry.”

Cushman & Wakefield’s RICS Award 2022 success in Hong Kong has also been matched in mainland China, with the firm taking top honors across multiple service lines, including Best Deal of the Year (Leasing), Research Team of the Year, Professional Consultancy Service Team of the Year — Real Estate (Valuation and Advisory Services), and Real Estate Financing Innovation Achievement of the Year. This dual recognition in mainland China and Hong Kong markets is indicative of the firm’s expertise and collaborative synergies that underpin its market leadership across the Greater China region.

John Siu, Managing Director, Hong Kong, Cushman & Wakefield, concluded, ” We are proud of our tradition of success at the RICS Hong Kong Awards, and such recognition from highly regarded and impartial third parties remain a clear demonstration of our ability to meet and exceed client needs.”

Please click HERE to download high-resolution photos.

Hashtag: #Cushman&Wakefield

About Cushman & Wakefield

Cushman & Wakefield (NYSE: CWK) is a leading global real estate services firm that delivers exceptional value for real estate occupiers and owners. Cushman & Wakefield is among the largest real estate services firms in the world, with approximately 50,000 employees in over 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region, earning recognition and winning multiple awards for industry-leading performance. In 2021, the firm had revenue of $9.4 billion across core services including valuation, consulting, project & development services, capital markets, project & occupier services, industrial & logistics, retail and others. To learn more, visit or follow on Twitter.

Grand Pharma’s Global Innovative Product STC3141 Achieved the Clinical Endpoint of The Phase Ib Clinical Trial for the Treatment of ARDS in China

  • According to the data analysis of the clinical trial, in the primary endpoint of the study, STC3141 did not suggest any potential serious safety problems or unexpected results in the overall safety profile, showing favorable safety and tolerance;
  • In the analysis of the secondary endpoint of efficacy, STC3141 showed positive signals compared with standard treatment method in terms of alleviating the severity of ARDS, improving the prognosis of ARDS patients, helping ARDS patients to be weaned off the ventilator and shortening the ICU length of stay;
  • The Phase IIa clinical study of STC3141 for the treatment of severe COVID-19 patients conducted in Europe has also achieved its clinical endpoint, with no serious drug-related adverse reactions, and the patients were well tolerated.

HONG KONG SAR – Media OutReach – 31 October 2022 – Grand Pharmaceutical Group Limited (“Grand Pharma“, stock code: 00512) announced that that the global innovative drug STC3141 in the field of severe disease, which is developed by its wholly-owned subsidiary Grand Medical Pty Ltd (an innovative drug R&D center set up by Grand Pharma in Australia), has successfully achieved the clinical study endpoint of the phase Ib clinical trial for the treatment of acute respiratory distress syndrome (“ARDS“) in China (“NCT05000671“).

NCT05000671 is a randomized, double-blind, placebo-controlled Phase Ib clinical study for investigating and evaluating the safety, tolerability and pharmacokinetics of the drug in patients with ARDS. The study received clinical approval for conducting clinical study from the National Medical Products Administration of the People’s Republic of China (NMPA) in March 2021 and completed the first patient enrollment in October, enrolled all patients in July 2022, and completed all follow-up and data analysis recently. A total of 16 evaluable subjects were enrolled in the study. All patients received standard intensive care unit (“ICU“) supported treatment and care appropriate to their conditions, adopting the principle of continuous 72-hour intravenous administration and dose-escalation grouped dosing. Subjects in each group were continuously observed until the 28th day after receiving treatment.

According to the data analysis of the clinical trial, in the primary endpoint of the study, STC3141 did not suggest any potential serious safety problems or unexpected results in the overall safety profile, showing favorable safety and tolerance. Meanwhile, in the analysis of the secondary endpoint of efficacy, STC3141 showed positive signals compared with standard treatment method in terms of alleviating the severity of ARDS, improving the prognosis of ARDS patients, helping ARDS patients to be weaned off the ventilator and shortening the ICU length of stay. It provides a solid foundation for further clinical research of the product.

ARDS is one of the main causes of death in ICU patients, and currently there is no effective medication treatment method in clinical practice. According to a statistical data related to nearly 30,000 patients in 459 ICUs of 50 countries around the world, the prevalence of ARDS is approximately 10.4% in critically ill patients, the overall mortality rate is approximately 34% in hospital, and mortality rate is approximately 60% in severe patients. In addition, among patients with severe COVID-19, ARDS is also one of the main causes of death, indicating an urgent clinical demand and tremendous market prospect.

STC3141 is a global innovative small molecule compound with a new mechanism of action independently developed by Grand Pharma. It can reverse the organ damage caused by the body’s excessive immune response by neutralizing extracellular free histones and neutrophil traps, and can be used for a variety of severe indications. The relevant preclinical research results of the product have been published in the top academic journal “Nature Communications” in February 2020, which has far-reaching academic influence.

In terms of clinical research, in addition to the Phase Ib clinical study for the treatment of ARDS patients conducted in China, the Phase IIa clinical study of STC3141 for the treatment of severe COVID-19 patients conducted in Europe has also achieved its clinical endpoint, with no serious drug-related adverse reactions, and the patients were well tolerated. Moreover, the product has approved to conduct Phase Ib clinical studies for the treatment of sepsis in Australia in May 2020 and in Belgium in April 2022, respectively, comprehensively promoting the international multi-center clinical trials.

Grand Pharma commented, “The achievement of the clinical endpoint in the Phase Ib clinical study in China of this project is not only an important milestone in the Group’s global clinical research process, but also provide solid data support for the subsequent clinical development of the product. In the future, the Group will continue to adopt the R&D concept of independent R&D and global expansion to create a full-cycle management product cluster for chronic airway diseases and a pipeline of anti-infection products for severe diseases, so as to continuously strengthen the Group’s industry position in this field.”

Hashtag: #GrandPharma

US Ambassador Donates to Conserve Ancient Wall Paintings in Savannakhet

Photo credit: Savanhphathana News

The US Ambassador to Laos, Mr. Peter Haymond has donated almost USD 50,000 to preserve wall paintings in three ancient temples in Savannakhet.